Startups
Rayca's agentic AI engine designs, simulates, and triages therapeutic candidates across modalities for hard-to-drug targets, with the institutional memory pharma has never had.
Mentions in press and media 3
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 20, 2026 | Three Swiss startups join DayOne's 2026 accelerator cohort | The DayOne Accelerator is a three-month hybrid program for early-stage ventures at the intersection of healthtech and pharma R&D. Run by Basel Area Business & Innovation, it chooses 15 startups a year at pre-seed to Series A stage.... |
| Jun 29, 2026 | Rayca Precision and Data Powered Therapeutics Partner to Advance AI-Designed Nanobody Cancer Therapeutics | Rayca Precision and Data Powered Therapeutics announce a strategic co-development partnership to advance AI-designed nanobody therapeutics for cancers of high unmet need. The collaboration unites Rayca's AI discovery engine with Data P... |
Reviews 0
FAQ about Rayca Precision
What has the press written about Rayca Precision?
Parsers VC has collected 3 articles mentioning Rayca Precision, among them “Three Swiss startups join DayOne's 2026 accelerator cohort” (Aug 20, 2026) and “Rayca Precision and Data Powered Therapeutics Partner to Advance AI-Designed Nanobody Cancer Therapeutics” (Jun 29, 2026).
Is Rayca Precision still active?
Yes, Rayca Precision is active; its latest activity on Parsers VC dates from Nov 3, 2026.